PLEASANTON, Calif., Aug. 24, 2015 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) has signed a definitive asset purchase agreement with Lumora for products associated with the unique, patent-protected Heat Elution1 technology for nucleic acid purification of multiple sample types including challenging formalin-fixed paraffin-embedded (FFPE) tumor samples. Roche plans to explore integrating this technology into its sequencing workflow solution. Today, nucleic acid purification technology from specimens including formalin-fixed tissues can be cumbersome and inefficient. Lumora's highly …